Table 6.

Salient molecular markers for NACT response prediction.

Biomarker	Summary
CA-125	Serum CA-125 is the most common tumor marker used at diagnosis and to observe treatment response. A >80% decrease in serum CA-125 level after NACT is found to be associated with optimal cytoreduction. Cut-off level to measure response/progression is still debatable.
Leptin	Higher serum CA-125 to ascites leptin ratio is found to be suggestive of baseline chemoresistance.
HE4	Serum HE4 level is found to be more valuable tumor marker in estimating surgery outcome. A >70% decrease in serum HE4 level after NACT is found to be associated with optimal cytoreduction.
ADLH1	Higher ALDH1 level after NACT is found to be associated with poor outcome and higher risk of death.
ADH1B	Higher preoperative ADH1B level is found be associated with higher chances of RD after tumor reductive surgery.
FABP4	Higher preoperative FABP4 level is found be associated with higher chances of RD after tumor reductive surgery.
MicroRNA	Higher level of specific MicroRNAs (Smad2 phosphorylation (P-Smad2), miR-181a-5p, miR-199a-5p and miR-199a-3p) is found to be associated with higher chances of RD after iTRS, decreased platinum-free interval and poor survival.
IGF-I	The presence of IGF-I in ascitic fluid is found to be an independent predictor of objective clinical response.
Calretinin	Higher serum CRT level is found to be associated with higher chances of suboptimal cytoreduction.
BRCA1/2	The presence of BRCA1/2 is found to be associated with higher chances of optimal cytoreduction and better survival.
c-Myc	c-Myc expression of >200 is found to be associated with better 5-year survival rate.